Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
Allergy Therapeutics plc (AGYTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.329x
Based on the latest financial reports, Allergy Therapeutics plc (AGYTF) has a cash flow conversion efficiency ratio of 0.329x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.00 Million) by net assets ($-63.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Allergy Therapeutics plc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Allergy Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Allergy Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allergy Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Optical Group Public Company Limited
BK:TOG
|
0.073x |
|
ATA Creativity Global
NASDAQ:AACG
|
0.007x |
|
Haulotte Group SA
PA:PIG
|
0.029x |
|
Multicampus Corporation
KQ:067280
|
0.038x |
|
KSP Co. Ltd.
KQ:073010
|
0.040x |
|
Chia Her Industrial Co Ltd
TW:1449
|
-0.001x |
|
STRUCT.MONIT.SYSCDIS
F:RJP
|
N/A |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Allergy Therapeutics plc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Allergy Therapeutics plc from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-63.88 Million | $-39.42 Million | 0.617x | +107.12% |
| 2024-06-30 | $3.71 Million | $-32.14 Million | -8.665x | +38.02% |
| 2023-06-30 | $2.07 Million | $-28.88 Million | -13.979x | -3634.75% |
| 2022-06-30 | $38.40 Million | $-14.37 Million | -0.374x | -316.30% |
| 2021-06-30 | $48.53 Million | $8.40 Million | 0.173x | -36.91% |
| 2020-06-30 | $43.78 Million | $12.01 Million | 0.274x | +83.97% |
| 2019-06-30 | $37.56 Million | $5.60 Million | 0.149x | +190.33% |
| 2018-06-30 | $23.03 Million | $-3.80 Million | -0.165x | -2878.67% |
| 2017-06-30 | $29.96 Million | $178.00K | 0.006x | +101.52% |
| 2016-06-30 | $30.32 Million | $-11.84 Million | -0.390x | -771.19% |
| 2015-06-30 | $34.47 Million | $2.00 Million | 0.058x | -59.65% |
| 2014-06-30 | $15.07 Million | $2.17 Million | 0.144x | -13.04% |
| 2013-06-30 | $14.67 Million | $2.43 Million | 0.166x | -16.01% |
| 2012-06-30 | $14.59 Million | $2.88 Million | 0.197x | +120.83% |
| 2011-06-30 | $2.14 Million | $-2.03 Million | -0.948x | -316.36% |
| 2010-06-30 | $3.89 Million | $1.70 Million | 0.438x | +2206.97% |
| 2009-06-30 | $-23.18 Million | $-440.00K | 0.019x | -98.89% |
| 2008-06-30 | $-11.29 Million | $-19.32 Million | 1.711x | +177.93% |
| 2007-06-30 | $8.60 Million | $-18.88 Million | -2.196x | -786.27% |
| 2006-06-30 | $32.70 Million | $-8.10 Million | -0.248x | -8630.66% |
| 2005-06-30 | $20.08 Million | $-57.00K | -0.003x | -101.05% |
| 2004-06-30 | $7.08 Million | $1.91 Million | 0.269x | -28.68% |
| 2003-06-30 | $5.55 Million | $2.10 Million | 0.378x | -17.28% |
| 2002-06-30 | $-4.40 Million | $-2.01 Million | 0.457x | -- |